News & Updates

Alcohol consumption contributes to increased mortality and major adverse cardiovascular events (MACE) among US veterans, with a J-shaped association indicating reduced risk at moderate consumption levels compared with abstinence of heavier drinking, suggests a study.

Adding carboplatin to doxorubicin and cyclophosphamide, followed by taxane therapy, results in significant improvement in event-free survival (EFS) among patients with early-stage triple-negative breast cancer (TNBC), as shown in the PEARLY trial.

New drug applications approved by US FDA as of 16-31 October 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Combination treatment with sacituzumab govitecan (SG) and pembrolizumab does not improve outcomes in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) unselected by programmed death-ligand 1 (PD-L1), as shown in a phase II trial.

More than one in five colorectal cancer (CRC) cases globally could be related to exposure to Helicobacter pylori, with China having the largest absolute number of CRC cases potentially linked to the bacterium, an international collaborative study led by investigators from the University of Hong Kong (HKU) has found.

Parallel testing of interleukin (IL)-10 to IL-6 and MYD88 demonstrates the highest diagnostic performance among strategies evaluated for primary vitreoretinal lymphoma (PVRL), suggests a study.

A phase II trial has demonstrated the safety and tolerability of combination treatment with intravesical cabazitaxel, gemcitabine, and cisplatin in patients with nonmuscle-invasive bacillus Calmette-Guérin (BCG)‒unresponsive urothelial carcinoma of the bladder.

In patients with suspected small bowel bleeding (SSBB), having a haemoglobin level of <8.0 g/dL appears to increase the risk of mortality, suggests a study.